Hyperion Therapeutics Inc., of Brisbane, Calif., said results of a phase II study of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) published in Hepatology showed that the trial met its primary endpoint, with significantly fewer patients treated with GPB experiencing HE events as compared to those receiving placebo.